Philippines Considers New Round Of Drug Price Caps Ahead Of Review
This article was originally published in PharmAsia News
Executive Summary
The Philippine government plans to expand its list of drugs carrying a price cap without waiting for a scheduled review of previous caps. The Health Department has a national study under way to determine candidate drugs for the next round of price reductions. The program's manager said the department also is considering whether to implement price caps every month or every other month. The first round of price controls, announced in July, ordered maximum drug retail prices on five essential drugs after drug makers voluntarily reduced the prices of 38 others. (Click here for more
You may also be interested in...
‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs
As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.